Technical Analysis for INVA - Innoviva, Inc.

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.